title: MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.
abstract: The interaction between osteoclasts (OCs) and multiple myeloma (MM) cells plays a key role in the pathogenesis of MM-related osteolytic bone disease (OBD). MM cells promote OC formation and, in turn, OCs enhance MM cell proliferation. Chemokines are mediators of MM effects on bone and vice versa; in particular, CCL3 enhances OC formation and promotes MM cell migration and survival. Here, we characterize the effects of MLN3897, a novel specific antagonist of the chemokine receptor CCR1, on both OC formation and OC-MM cell interactions. MLN3897 demonstrates significant impairment of OC formation (by 40%) and function (by 70%), associated with decreased precursor cell multinucleation and down-regulation of c-fos signaling. OCs secrete high levels of CCL3, which triggers MM cell migration; conversely, MLN3897 abrogates its effects by inhibiting Akt signaling. Moreover, MM cell-to-OC adhesion was abrogated by MLN3897, thereby inhibiting MM cell survival and proliferation. Our results therefore show novel biologic sequelae of CCL3 and its inhibition in both osteoclastogenesis and MM cell growth, providing the preclinical rationale for clinical trials of MLN3897 to treat OBD in MM.
authors: Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
authors: Sonia
authors: S
authors: Vallet
authors: Noopur
authors: N
authors: Raje
authors: Kenji
authors: K
authors: Ishitsuka
authors: Teru
authors: T
authors: Hideshima
authors: Klaus
authors: K
authors: Podar
authors: Shweta
authors: S
authors: Chhetri
authors: Samantha
authors: S
authors: Pozzi
authors: Iris
authors: I
authors: Breitkreutz
authors: Tanyel
authors: T
authors: Kiziltepe
authors: Hiroshi
authors: H
authors: Yasui
authors: Enrique M
authors: EM
authors: Ocio
authors: Norihiko
authors: N
authors: Shiraishi
authors: Janice
authors: J
authors: Jin
authors: Yutaka
authors: Y
authors: Okawa
authors: Hiroshi
authors: H
authors: Ikeda
authors: Siddhartha
authors: S
authors: Mukherjee
authors: Nileshwari
authors: N
authors: Vaghela
authors: Diana
authors: D
authors: Cirstea
authors: Marco
authors: M
authors: Ladetto
authors: Mario
authors: M
authors: Boccadoro
authors: Kenneth C
authors: KC
authors: Anderson
mesh_terms: D002448:Cell Adhesion / Q000187:drug effects; D002450:Cell Communication / Q000187:drug effects*; D002454:Cell Differentiation / Q000187:drug effects; D002459:Cell Fusion; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D054405:Chemokine CCL3 / Q000378:metabolism; D015536:Down-Regulation / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D016762:Genes, fos; D006801:Humans; D009101:Multiple Myeloma / Q000378:metabolism / Q000473:pathology*; D010010:Osteoclasts / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology*; D054389:Receptors, CCR1 / Q000037:antagonists & inhibitors*
chemical_list: D054405:Chemokine CCL3; D054389:Receptors, CCR1
references: Blood. 2000 Jul 15;96(2):671-5
references: 10887133
references: Blood. 1995 Oct 15;86(8):3151-9
references: 7579410
references: Blood. 2001 Jun 1;97(11):3349-53
references: 11369623
references: J Clin Invest. 2001 Dec;108(12):1833-41
references: 11748267
references: Hematol J. 2001;2(1):42-53
references: 11920233
references: Blood. 2002 Jun 15;99(12):4646-7; author reply 4647
references: 12066787
references: J Cell Biol. 1996 Aug;134(4):1063-73
references: 8769427
references: Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10939-44
references: 8855287
references: J Bone Miner Res. 2004 Dec;19(12):2065-77
references: 15537451
references: Exp Hematol. 2005 Mar;33(3):272-8
references: 15730850
references: Br J Cancer. 2005 Apr 25;92(8):1531-7
references: 15812559
references: Blood. 2005 Jul 15;106(2):713-6
references: 15817674
references: Ann N Y Acad Sci. 2005 Jun;1051:647-57
references: 16127005
references: Oncogene. 2005 Sep 1;24(38):5897-904
references: 16007209
references: J Bone Miner Res. 2006 Jan;21(1):48-57
references: 16355273
references: J Biol Chem. 2006 Jan 13;281(2):1274-85
references: 16280328
references: J Cell Biochem. 2006 Feb 15;97(3):512-8
references: 16211583
references: N Engl J Med. 2006 Feb 9;354(6):610-21
references: 16467548
references: Clin Exp Metastasis. 2006;23(1):9-18
references: 16821125
references: Clin Exp Metastasis. 2006;23(5-6):291-300
references: 17086356
references: J Cell Biochem. 2007 May 1;101(1):122-34
references: 17171644
references: Blood. 2007 Jul 15;110(2):709-18
references: 17384201
references: Nat Cell Biol. 2002 Aug;4(8):556-64
references: 12134156
references: Blood. 2002 Sep 15;100(6):2195-202
references: 12200385
references: J Cell Biochem. 2002;87(4):386-93
references: 12397598
references: J Biol Chem. 2002 Oct 25;277(43):41147-56
references: 12171919
references: Leukemia. 2003 Jan;17(1):203-10
references: 12529679
references: Cancer. 2003 Feb 1;97(3 Suppl):859-65
references: 12548587
references: J Clin Invest. 2003 Mar;111(5):749-58
references: 12618529
references: Br J Cancer. 2003 Mar 24;88(6):855-62
references: 12644822
references: Blood. 2003 May 1;101(9):3568-73
references: 12506012
references: Blood. 2003 Jul 1;102(1):311-9
references: 12649140
references: Eur J Immunol. 2004 Mar;34(3):785-95
references: 14991608
references: Biochem Biophys Res Commun. 2004 Apr 2;316(2):573-9
references: 15020256
references: J Biol Chem. 2004 Aug 6;279(32):33567-74
references: 15136564
references: Blood. 2004 Oct 15;104(8):2484-91
references: 15187021
references: Science. 1994 Oct 21;266(5184):443-8
references: 7939685
references: J Exp Med. 2000 Aug 21;192(4):495-506
references: 10952719